



Received: 10-11-2023  
Accepted: 20-12-2023

ISSN: 2583-049X

## **Development and Implementation of an AI-Driven Early Detection System for Non-Communicable Diseases**

<sup>1</sup> Erica Afrihyia, <sup>2</sup> Salewa Gloria Akinse, <sup>3</sup> Prisca U Ojukwu

<sup>1</sup> Independent Researcher, Ohio, USA

<sup>2</sup> Standard Atlantic Resources Uyo, Nigeria

<sup>3</sup> Nnamdi Azikiwe University, Nigeria

Corresponding Author: **Erica Afrihyia**

### **Abstract**

Non-Communicable Diseases (NCDs), including cardiovascular diseases, diabetes, cancer, and chronic respiratory conditions, pose a significant global health burden, accounting for over 70% of deaths worldwide. Early detection is crucial for effective intervention, reducing morbidity, and improving patient outcomes. The integration of Artificial Intelligence (AI) in healthcare has demonstrated substantial potential in revolutionizing early detection systems through predictive analytics, machine learning, and big data processing. This explores the development and implementation of an AI-driven early detection system for NCDs, focusing on leveraging diverse data sources such as electronic health records (EHRs), wearable health devices, and genetic information. The proposed system utilizes machine learning models to identify patterns, assess risk factors, and provide early warnings, enabling timely medical intervention. Key components of the system include data acquisition and preprocessing, model selection and training, integration with healthcare infrastructure, and deployment strategies ensuring reliability and scalability. The

implementation phase involves collaboration with healthcare providers to validate AI models, ensuring accuracy, fairness, and compliance with healthcare regulations such as HIPAA and GDPR. Ethical considerations, including data privacy, algorithmic bias, and patient trust, are critical in system adoption. Case studies of AI-based early detection programs highlight successes, challenges, and lessons for future advancements. This also discusses future directions in AI-driven preventive healthcare, emphasizing the role of personalized medicine and real-time monitoring. With continuous advancements in AI and big data analytics, AI-powered early detection systems offer transformative potential in reducing the NCD burden, ultimately improving public health and healthcare efficiency. However, challenges in model interpretability, regulatory compliance, and system integration must be addressed for widespread adoption. This review underscores AI's potential to enhance early detection, optimize healthcare delivery, and shape the future of proactive disease management.

**Keywords:** AI-Driven, Early Detection System, Non-Communicable Diseases, Review

### **1. Introduction**

Non-Communicable Diseases (NCDs) represent a major global health challenge, accounting for over 70% of deaths worldwide (Adelodun *et al.*, 2018) <sup>[1]</sup>. Unlike infectious diseases, NCDs are chronic conditions that progress slowly and are primarily caused by genetic, environmental, and lifestyle factors. The most prevalent NCDs include cardiovascular diseases, diabetes, chronic respiratory diseases, and cancer. According to the World Health Organization (WHO), NCDs disproportionately affect low- and middle-income countries, where healthcare resources are often limited, and preventive measures are inadequate (Tomassoni *et al.*, 2013; Matthew *et al.*, 2021). Risk factors such as poor diet, sedentary lifestyles, tobacco use, and excessive alcohol consumption contribute significantly to the rising incidence of NCDs (Jahun *et al.*, 2021). Without timely intervention, these conditions lead to severe complications, disability, and increased healthcare costs, placing a heavy burden on individuals and healthcare systems.

Early detection of NCDs is essential for improving patient outcomes, reducing disease progression, and minimizing healthcare costs. (Austin-Gabriel *et al.*, 2021) <sup>[12]</sup> Many NCDs remain asymptomatic in their initial stages, leading to delayed diagnoses

and late-stage interventions that are less effective and more costly. For example, early identification of hypertension or prediabetes can prevent the development of life-threatening conditions such as heart attacks, strokes, and kidney failure. Similarly, early cancer detection significantly improves survival rates, as treatment options are more effective in the initial stages of the disease. Implementing robust early detection strategies enables timely medical interventions, lifestyle modifications, and disease management plans, ultimately reducing morbidity and mortality. Traditional screening methods, however, are often resource-intensive and may not be accessible to all populations, highlighting the need for advanced, technology-driven solutions (Hussain *et al.*, 2021) [24].

Artificial Intelligence (AI) is revolutionizing healthcare by enhancing diagnostic accuracy, personalizing treatment plans, and optimizing disease prevention strategies (Adepoju *et al.*, 2022) [2]. AI-driven early detection systems leverage machine learning algorithms, deep learning, and big data analytics to identify disease patterns, predict risk factors, and detect abnormalities in medical data. By analyzing vast amounts of structured and unstructured health data such as electronic health records (EHRs), imaging scans, wearable device outputs, and genomic information AI can provide real-time insights for clinicians. In the context of NCD detection, AI enables the development of predictive models that assess individual risk profiles, allowing for proactive intervention. Furthermore, AI enhances telemedicine and remote monitoring by integrating with mobile health applications and wearable devices, allowing continuous health tracking and automated alerts for high-risk individuals (Ike *et al.*, 2021) [25]. Despite these advancements, challenges such as data privacy concerns, algorithm bias, and integration into existing healthcare workflows remain key considerations in AI adoption.

The primary objective of an AI-driven early detection system for NCDs is to enhance predictive accuracy and facilitate timely medical intervention (Oladosu *et al.*, 2021) [43]. This system aims to; AI algorithms will analyze health data to identify early-stage disease markers, providing timely alerts to healthcare providers and patients. The system will evaluate lifestyle, genetic, and environmental factors to predict an individual's susceptibility to NCDs, enabling personalized preventive strategies. AI models will be designed to seamlessly integrate with EHRs, wearable health technologies, and diagnostic tools to ensure accessibility and ease of use. Early detection and intervention will decrease the need for expensive late-stage treatments, ultimately reducing financial burdens on healthcare systems (Tomassoni *et al.*, 2013). Addressing concerns such as data privacy, algorithm bias, and healthcare disparities will be fundamental to the system's deployment. By leveraging AI's potential, this system seeks to transform the landscape of NCD management, shifting healthcare from a reactive to a proactive model. AI-driven early detection has the potential to save millions of lives, improve healthcare efficiency, and promote global health equity (Kuo *et al.*, 2019) [31]. However, its successful implementation requires collaboration between technology developers, healthcare professionals, and policymakers to address challenges and maximize its benefits.

## 2. Methodology

The PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) methodology was applied to conduct a systematic review on the development and implementation of an AI-driven early detection system for Non-Communicable Diseases (NCDs). A structured and transparent approach was used to ensure comprehensive data collection, analysis, and reporting.

A systematic search was conducted across major scientific databases, including PubMed, IEEE Xplore, Scopus, and Web of Science, focusing on publications from the last ten years to capture recent advancements in AI-driven disease detection. The search strategy incorporated a combination of keywords and Medical Subject Headings (MeSH) terms such as "Artificial Intelligence," "Machine Learning," "Early Detection," "Non-Communicable Diseases," and "Predictive Analytics." Relevant studies were identified based on predefined inclusion and exclusion criteria. Studies were included if they focused on AI-based early detection models for NCDs, employed machine learning or deep learning techniques, and demonstrated clinical validation or real-world applications. Exclusion criteria encompassed studies lacking methodological transparency, those focused on communicable diseases, and non-English publications.

Following the search, duplicate records were removed using reference management software. A two-stage screening process was conducted, beginning with title and abstract screening, followed by a full-text review of eligible studies. Two independent reviewers assessed each study to minimize bias, and discrepancies were resolved through discussion or by consulting a third reviewer. The quality of included studies was evaluated using standard appraisal tools such as the Critical Appraisal Skills Programme (CASP) checklist and the Newcastle-Ottawa Scale (NOS). Data extraction was performed using a structured template, collecting information on study design, AI methodologies, data sources, validation techniques, and key findings relevant to AI-driven early detection of NCDs.

A systematic synthesis of the results was conducted, involving both qualitative and quantitative analyses. Key themes, including AI model performance, data integration challenges, and ethical considerations, were identified. Where applicable, statistical methods such as meta-analysis or descriptive synthesis were employed to evaluate AI effectiveness in early disease detection. The risk of bias was assessed using the Cochrane Risk of Bias Tool to ensure the reliability and validity of the findings.

Applying the PRISMA methodology in this review facilitated a rigorous evaluation of AI-driven early detection systems for NCDs. The systematic approach provided evidence-based insights into AI effectiveness, implementation challenges, and future research directions. This methodology contributes to the development of robust, scalable, and clinically validated AI-driven solutions, promoting early diagnosis and improved healthcare outcomes for NCD management.

### 2.1 Understanding Non-Communicable Diseases (NCDs)

Non-Communicable Diseases (NCDs) are chronic medical conditions that are not caused by infectious agents and typically progress slowly over time (Elujide *et al.*, 2021).

Unlike communicable diseases, which spread from person to person through pathogens, NCDs arise from a combination of genetic, lifestyle, and environmental factors. The World Health Organization (WHO) classifies NCDs into four major categories: cardiovascular diseases (such as heart attacks and strokes), cancers, chronic respiratory diseases (such as chronic obstructive pulmonary disease and asthma), and diabetes. Additionally, other significant NCDs include neurodegenerative disorders (such as Alzheimer's disease), mental health conditions, and chronic kidney disease. These diseases are often lifelong and require ongoing medical management, contributing significantly to global healthcare challenges.

NCDs are the leading cause of death and disability worldwide, accounting for approximately 74% of all global deaths, with a disproportionate burden on low- and middle-income countries. According to WHO data, cardiovascular diseases alone are responsible for nearly 18 million deaths annually, making them the most common cause of mortality among NCDs (Olamijuwon, 2020) [44]. Cancer claims around 10 million lives each year, while chronic respiratory diseases and diabetes together contribute to millions of additional deaths. The increasing prevalence of NCDs places immense strain on healthcare systems, economies, and communities. Beyond mortality, NCDs significantly impact the quality of life and productivity of affected individuals. Chronic conditions lead to prolonged disability, increased dependency, and substantial economic costs due to long-term medical treatments and loss of workforce productivity. The economic burden of NCDs extends beyond direct medical costs to include indirect costs, such as reduced labor force participation and increased caregiving demands. Given the growing global burden, addressing NCDs through improved detection, prevention, and management has become a priority in public health initiatives.

The development of NCDs is influenced by a complex interplay of genetic predisposition, lifestyle choices, and environmental factors (Oyedokun, 2019) [46]. Some individuals have a hereditary susceptibility to NCDs, meaning they inherit genetic mutations that increase their risk. For example, individuals with a family history of cardiovascular disease or diabetes are more likely to develop these conditions. Similarly, genetic mutations play a critical role in certain types of cancer, such as breast and colorectal cancer. While genetic predisposition alone does not cause NCDs, it interacts with environmental and lifestyle factors to determine disease onset and progression. Unhealthy behaviors are among the most significant contributors to NCDs. Poor dietary habits, such as excessive consumption of processed foods, high sugar intake, and unhealthy fats, contribute to obesity, diabetes, and cardiovascular diseases. Physical inactivity is another major risk factor, as a sedentary lifestyle leads to weight gain, metabolic disorders, and increased cardiovascular risks (Oladosu *et al.*, 2021) [43]. Additionally, tobacco use and excessive alcohol consumption are linked to numerous NCDs, including lung cancer, liver disease, and hypertension. Smoking, in particular, is a major cause of chronic respiratory diseases and cardiovascular complications. Environmental factors, including air pollution, exposure to toxic substances, and socioeconomic conditions, also play a crucial role in the development of NCDs. Long-term exposure to air pollution has been linked to respiratory diseases, cardiovascular

problems, and an increased risk of cancer. Occupational hazards, such as prolonged exposure to chemicals or radiation, further elevate the risk of developing chronic illnesses. Socioeconomic status influences access to healthcare, nutritious food, and education about healthy lifestyles, contributing to disparities in NCD prevalence and outcomes.

Despite the well-documented risk factors of NCDs, their early detection and diagnosis remain a significant challenge. Traditional diagnostic methods often rely on periodic health check-ups, clinical symptoms, and manual screening procedures, which are not always effective in identifying diseases at an early stage (Agho *et al.*, 2021) [4]. Many NCDs, such as hypertension, diabetes, and certain types of cancer, remain asymptomatic in their initial stages, leading to late diagnosis and delayed medical intervention. Access to healthcare is another major barrier to early detection. In many low- and middle-income countries, there is limited availability of advanced diagnostic tools, trained healthcare professionals, and affordable screening programs. As a result, individuals often seek medical attention only when symptoms become severe, by which time the disease has already progressed to a more critical stage. This delayed diagnosis reduces treatment efficacy, increases healthcare costs, and worsens patient outcomes. Additionally, traditional screening methods can be invasive, time-consuming, and resource-intensive. For example, detecting cardiovascular diseases often requires multiple tests, including electrocardiograms (ECG), echocardiography, and blood tests, which may not be readily available in remote or underserved areas. Similarly, cancer screening techniques such as biopsies, mammograms, and colonoscopies are costly and may not be accessible to all populations. Another challenge is the variability in diagnostic accuracy. Human error, subjective interpretations, and inconsistencies in medical evaluations can lead to misdiagnosis or missed diagnoses (Nwaozumudoh *et al.*, 2021) [41]. This is particularly concerning in diseases where early intervention is critical, such as cancer and diabetes. Furthermore, reliance on self-reported symptoms can result in underestimation or misclassification of disease risks. To overcome these challenges, there is an urgent need for more efficient, scalable, and cost-effective diagnostic approaches. The integration of artificial intelligence (AI) into healthcare offers promising solutions by enhancing early detection capabilities, reducing diagnostic errors, and improving accessibility to medical screening (Oodio *et al.*, 2021) [42]. AI-driven systems can analyze vast amounts of health data, identify disease patterns, and predict NCD risks with high accuracy. By leveraging technology, healthcare systems can shift from reactive treatment models to proactive disease prevention and early intervention strategies, ultimately reducing the burden of NCDs on individuals and societies. Understanding NCDs and the challenges associated with their detection underscores the need for innovative approaches to disease prevention and management. As AI continues to advance, it holds the potential to revolutionize healthcare by enabling early diagnosis, personalized treatment plans, and improved health outcomes for millions of individuals (Dienagha *et al.*, 2021; Oluokun, 2021) [16, 45].


## 2.2 AI Technologies for Early Detection of NCDs

Artificial Intelligence (AI) is revolutionizing healthcare by enabling the early detection of Non-Communicable Diseases

(NCDs) through advanced predictive modeling and diagnostic tools (Adewoyin, 2021) [3]. AI-driven systems utilize machine learning (ML) and deep learning (DL) techniques to analyze vast amounts of health data, identify disease patterns, and enhance decision-making in clinical settings as shown in figure 1. The integration of diverse data sources, feature engineering techniques, and AI-based diagnostic tools has significantly improved the accuracy and efficiency of NCD detection.

Machine learning and deep learning are two core AI techniques used for detecting NCDs at an early stage. Machine learning involves training algorithms to recognize patterns in medical data and make predictions based on statistical models. Supervised learning, a common ML approach, uses labeled data to train models for disease prediction. Deep learning, a subset of ML, utilizes artificial neural networks to automatically learn hierarchical representations of data. Convolutional Neural Networks (CNNs) are widely used in medical imaging analysis, enabling early detection of conditions such as lung cancer and diabetic retinopathy from radiological scans. Recurrent Neural Networks (RNNs) and Long Short-Term Memory (LSTM) networks are applied in sequential health data analysis, such as monitoring changes in heart rate variability from wearable devices to predict cardiovascular events. The advantage of deep learning lies in its ability to handle complex, high-dimensional datasets, making it particularly effective in detecting subtle disease markers that might be overlooked by traditional diagnostic methods (Akinade *et al.*, 2021 [6]; Elujide *et al.*, 2021). The effectiveness of AI-driven NCD detection relies on the integration of multiple data sources, each providing valuable insights into an individual's health status.

Electronic Health Records (EHRs), serve as a primary data source for AI-driven disease detection. These records contain structured and unstructured medical data, including patient demographics, laboratory test results, medication history, and clinical notes. AI algorithms process this data to identify risk factors, detect disease progression, and generate early warning alerts (Hassan *et al.*, 2021) [22]. Natural Language Processing (NLP) techniques help extract meaningful information from unstructured text in clinical reports, improving the accuracy of predictive models. Wearable Devices: The rise of wearable health-monitoring devices has introduced real-time physiological data into AI-based early detection systems. Smartwatches, fitness trackers, and biosensors continuously collect metrics such as heart rate, blood pressure, glucose levels, and sleep patterns (Ajayi and Akerele, 2021) [5]. AI models analyze this data to detect anomalies and predict the onset of NCDs such as hypertension and diabetes. The continuous nature of wearable data allows for early intervention, reducing the risk of severe complications. Genomic Data: Advances in genomics have enabled AI to incorporate genetic risk factors into NCD prediction. Genomic sequencing data can identify hereditary predispositions to conditions like cancer, cardiovascular diseases, and neurodegenerative disorders. AI algorithms analyze genetic variations and epigenetic markers to assess an individual's likelihood of developing specific NCDs, allowing for personalized preventive strategies. Integrating genomic data with clinical and lifestyle information enhances the precision of predictive models.



**Fig 1:** AI Technologies for Early Detection of NCDs

Feature engineering is a crucial step in AI-driven early detection, as it transforms raw data into meaningful inputs for machine learning models (Tomassoni *et al.*, 2013). The selection of relevant features significantly impacts the performance of predictive models. For structured data, feature engineering involves extracting statistical measures such as mean, variance, and trend analysis from physiological readings. In medical imaging, feature extraction techniques identify key biomarkers from radiographic scans. Texture analysis, shape detection, and intensity variations in medical images help AI models differentiate between benign and malignant tumors. CNNs automate feature extraction from medical images, reducing the need for manual intervention. For textual data, NLP techniques such as tokenization, named entity recognition, and sentiment analysis extract clinically relevant information from doctor's notes and patient records (Tayebati *et al.*, 2013). These features improve AI's ability to detect early symptoms and recommend appropriate diagnostic tests. Dimensionality reduction techniques such as Principal Component Analysis (PCA) and autoencoders help eliminate redundant features, improving computational efficiency while preserving important predictive information. By refining input features, AI models achieve higher accuracy in detecting early-stage NCDs.

AI-based diagnostic tools have transformed the early detection of NCDs by leveraging advanced computational techniques to analyze medical imaging, biomarkers, and clinical text (Nasuti *et al.*, 2008) [39]. AI-powered image analysis has significantly improved the early detection of NCDs such as cancer, cardiovascular diseases, and neurological disorders. CNN-based deep learning models analyze radiology images, including X-rays, MRIs, and CT scans, to detect abnormalities with high precision. For example, AI-assisted mammography enhances breast cancer detection by identifying malignant tumors at an early stage. AI-driven retinal imaging systems detect diabetic retinopathy by analyzing retinal blood vessel abnormalities. The automation of image interpretation reduces diagnostic errors and speeds up clinical decision-making. Biomarkers, such as blood protein levels and metabolic indicators, play a critical role in early disease detection (Tayebati *et al.*, 2013). AI models analyze laboratory test results to identify biomarker patterns associated with NCDs. For instance, AI-driven blood tests can detect early signs of liver disease by analyzing liver enzyme levels. Machine learning algorithms assess multiple biomarkers simultaneously, improving disease risk assessment and early diagnosis. The integration of omics data (genomics, proteomics, and metabolomics) further enhances the predictive power of AI in identifying disease susceptibility. NLP enables AI systems to extract valuable insights from unstructured clinical text, including

patient histories, doctor's notes, and medical literature. AI-driven chatbots and virtual assistants use NLP to analyze patient-reported symptoms and provide preliminary assessments for potential NCDs. NLP models also assist in automated medical coding, ensuring accurate documentation of disease conditions in EHRs. By processing large volumes of medical text, NLP enhances early disease recognition and clinical decision support (Tomassoni *et al.*, 2012) [60]. AI technologies have revolutionized the early detection of NCDs by integrating machine learning, deep learning, and data-driven diagnostic tools. The use of electronic health records, wearable devices, and genomic data enables AI to provide personalized risk assessments and early intervention strategies. Feature engineering plays a critical role in refining predictive models, ensuring higher accuracy in disease detection. AI-based diagnostic tools, including medical imaging analysis, biomarker assessment, and NLP techniques, enhance clinical decision-making and improve patient outcomes. As AI continues to evolve, its potential to transform NCD prevention and early detection will further enhance global healthcare strategies, reducing morbidity and mortality associated with chronic diseases (Alli and Dada, 2021) [9].

### 2.3 System Development and Architecture

The development of an AI-driven early detection system for Non-Communicable Diseases (NCDs) requires a well-structured system architecture that integrates multiple components, including data processing, AI model training, and a user interface for clinical deployment (Matthew *et al.*, 2021). Ensuring the accuracy, reliability, and explainability of AI predictions is crucial for successful implementation. This explores the key aspects of system development, covering system components, algorithm selection, integration with healthcare infrastructure, and model performance optimization.

The system architecture consists of three primary components as shown in figure 2; Data processing module, this component is responsible for collecting, cleaning, and preprocessing data from various sources such as; Structured and unstructured medical records that provide historical patient data. Real-time physiological data, such as heart rate, blood pressure, and glucose levels. Radiology scans, X-rays, MRIs, and CT scans used for AI-based diagnostics. Genetic sequencing and biochemical markers linked to NCDs (Jahun *et al.*, 2021). The data processing pipeline involves handling missing values, normalizing data, feature extraction, and anonymization to ensure compliance with healthcare privacy regulations.




Fig 2: System development and architecture

The AI model training module consists of; Selecting the most relevant data attributes for predictive modeling. Applying machine learning (ML) and deep learning (DL) techniques to detect early disease markers (Bidemi *et al.*, 2021) [14]. Evaluating model performance using separate datasets to prevent overfitting. Fine-tuning hyperparameters to enhance accuracy and generalizability. The system requires an intuitive UI for clinical use, ensuring seamless interaction between healthcare professionals and AI-driven insights. The UI includes; Displays patient risk scores, diagnostic reports, and suggested interventions. Provides real-time health tracking and personalized recommendations (Dirlikov *et al.*, 2021) [17]. Connects AI predictions with hospital information systems (HIS) and electronic medical records. The selection of appropriate AI algorithms is critical for accurate and efficient NCD detection. The model training process follows several key steps;

Decision trees, random forests, and support vector machines (SVM) are used for structured data analysis. Convolutional Neural Networks (CNNs) for imaging diagnostics and Recurrent Neural Networks (RNNs) for sequential health data. Combining ML and DL approaches to improve predictive performance (Atta *et al.*, 2021) [11]. The training process includes; Dividing datasets into training (70%), validation (15%), and testing (15%) sets. Identifying relevant biomarkers, genetic variations, and lifestyle factors. Adjusting learning rates, activation functions, and layer structures to enhance model performance. Using k-fold cross-validation to prevent bias and improve model generalization. The effectiveness of the trained AI model is assessed using;

Measures the correctness of disease predictions. Evaluates the system's ability to detect true disease cases (Ali *et al.*, 2019) [8]. Ensures minimal false positives to avoid unnecessary medical interventions. Balances precision and recall for optimal model performance. For effective deployment, the AI system must seamlessly integrate with current healthcare technologies. The integration process involves; Standardized data exchange protocols such as HL7 and FHIR ensure smooth interoperability. API-based integration allows AI models to retrieve and update patient data in real time. Allow remote access to AI predictions and centralized model updates. Enables on-device analysis for wearable health monitoring, reducing latency in real-time predictions. Compliance with regulatory standards; Ensuring adherence to HIPAA, GDPR, and FDA guidelines for data privacy and security. Conducting clinical trials to validate AI system reliability before full-scale implementation (Senbekov *et al.*, 2020) [50].

A key challenge in AI-driven healthcare is ensuring that the system delivers reliable, explainable, and accurate predictions to gain clinical trust (Amann *et al.*, 2020) [10]. Enhancing training datasets with synthetic samples to improve model robustness. Adjusting probability outputs to align with real-world disease prevalence. Implementing reinforcement learning to update AI models based on new clinical data. To build clinician confidence in AI-driven decisions, the system incorporates explainability techniques; SHAP (Shapley Additive Explanations), provides feature importance scores to show which factors influenced the prediction. LIME (Local Interpretable Model-Agnostic Explanations), generates human-readable explanations for individual predictions. Highlights areas in medical images that contributed to diagnosis, aiding radiologists in decision-

making. Handling ethical and bias concerns (Makanjee, 2021) [34]. Regular audits to ensure fairness across demographic groups. Involving healthcare professionals in final decision-making. Implementation and Deployment Strategies for an AI-Driven Early Detection System for non-communicable diseases the successful implementation and deployment of an AI-driven early detection system for non-communicable diseases (NCDs) require a well-structured approach (Schwalbe and Wahl, 2020; Naseem *et al.*, 2020) [49, 38]. This includes efficient data collection and preprocessing, rigorous model validation, strategic deployment decisions (cloud-based vs. on-premises), integration with healthcare systems, and the training of healthcare professionals. Each of these factors plays a crucial role in ensuring the system's reliability, scalability, and adoption within the medical community.

The AI system relies on diverse datasets to improve predictive accuracy. These include; Medical histories, diagnostic tests, prescriptions, and physician notes. Continuous monitoring of vital signs like heart rate, glucose levels, and blood pressure (Soon *et al.*, 2020) [52]. CT scans, MRIs, and X-rays provide crucial visual biomarkers for AI-driven analysis. Genetic predisposition and biomolecular markers for risk stratification. Lifestyle factors such as diet, smoking habits, and physical activity levels. To ensure high-quality inputs for AI models, preprocessing steps include; Handling missing values through imputation techniques and removing inconsistencies. Selecting relevant predictors, such as genetic markers, age, or comorbidities. Converting data into uniform formats for ML model compatibility. Protecting patient privacy through encryption and de-identification. Before deployment, the AI system undergoes rigorous validation to ensure clinical reliability; Splitting data into training, validation, and testing sets to prevent overfitting (Mahmood *et al.*, 2021) [33]. Adjusting parameters such as learning rates and regularization techniques. Identifying and mitigating biases to ensure fair predictions across demographics. Model effectiveness is evaluated using key metrics; Measures overall correctness of disease classification. Balances false positives (misdiagnosing healthy individuals) and false negatives (missing true cases). Provides a harmonic mean of precision and recall. Evaluates the model's ability to distinguish between diseased and healthy patients. These metrics are benchmarked against clinical standards to assess readiness for real-world application. Cloud computing offers scalable, remote access to AI-driven healthcare systems. Benefits include; Reduced hardware and maintenance costs. Enables remote monitoring and updates. Easily handles increasing data loads and multiple hospital networks. Requires robust encryption and compliance with privacy laws (HIPAA, GDPR). Hospitals may opt for on-site deployment for greater control and data security. Advantages include; Meets stringent data protection regulations. Faster real-time processing without internet dependency. Requires significant infrastructure and IT maintenance. The choice between cloud-based and on-premises deployment depends on factors like budget, regulatory constraints, and scalability requirements (Hughes *et al.*, 2021) [23]. Integration with healthcare providers and telemedicine platforms;

AI models integrate with existing hospital IT systems via HL7 or FHIR protocols. Alerts physicians when high-risk patients are detected. Provides AI-assisted insights for early interventions. Telemedicine and remote monitoring; Patients

with smart health devices can transmit real-time vitals for AI assessment (Jeddi and Bohr, 2020) [29]. AI-generated reports enhance telemedicine efficiency. Helps triage patients based on severity levels. Seamless integration ensures that both in-clinic and remote patients benefit from AI-powered early detection tools. User training and adoption by healthcare professionals; Helps clinicians interpret AI-generated reports. Encourages formal AI literacy among healthcare professionals. AI engineers work closely with doctors to refine usability. Addressing resistance to AI adoption; Explainable AI (XAI) techniques help doctors understand AI decisions. Demonstrating model reliability through peer-reviewed trials. FDA and medical board endorsements increase clinician trust (Mooney *et al.*, 2019) [37]. Continuous feedback and system optimization; Gather feedback from doctors and patients. AI continuously learns from new medical data to improve accuracy. Ongoing monitoring ensures adherence to clinical best practices. The implementation and deployment of an AI-driven early detection system for NCDs require robust strategies across multiple dimensions. Effective data collection and preprocessing ensure high-quality model inputs, while rigorous validation and performance benchmarking establish reliability. Deployment strategies, whether cloud-based or on-premises, must balance scalability, cost, and security considerations. Seamless integration with healthcare providers and telemedicine platforms enhances accessibility, while targeted training programs facilitate clinician adoption. By addressing these critical factors, AI-powered early detection systems can significantly enhance healthcare outcomes, enabling proactive interventions and reducing the global burden of NCDs.


## 2.4 Ethical and Regulatory Considerations

The development and implementation of AI-driven early detection systems for Non-Communicable Diseases (NCDs) require careful consideration of ethical and regulatory aspects (Shiroya *et al.*, 2019) [51]. As AI technologies are integrated into healthcare, concerns regarding patient privacy, data security, model fairness, regulatory compliance, and ethical decision-making must be addressed as shown in figure 3. Ensuring transparency, accountability, and compliance with healthcare laws is critical to fostering trust among healthcare providers and patients. AI-driven healthcare systems rely on vast amounts of sensitive patient data, including electronic health records (EHRs), genomic information, wearable device data, and medical imaging. Protecting this data from breaches, unauthorized access, and misuse is paramount to maintaining patient trust and ensuring regulatory compliance. To safeguard patient privacy, AI systems must incorporate robust cybersecurity measures, including;

Ensuring secure storage and transmission of patient data. Restricting data access to authorized personnel only. Removing personally identifiable information to minimize risks in case of data breaches. Providing decentralized and tamper-proof data storage. Healthcare databases are prime targets for cyberattacks, leading to potential identity theft, insurance fraud, and unauthorized exploitation of medical data. Implementing strong security frameworks and conducting regular vulnerability assessments are essential to preventing data breaches. Bias in AI models can lead to disparities in healthcare outcomes, disproportionately affecting certain demographic groups (Paulus and Kent,

2020) [47]. Bias arises from; Over representation or under representation of specific populations.

Existing biases in healthcare records influencing AI predictions. Model structures that fail to account for diversity in health conditions. To ensure fairness and inclusivity in AI-driven healthcare systems, developers must; Incorporate data from different racial, ethnic, and socioeconomic groups. Continuously monitor predictions for signs of bias. Implement algorithmic techniques to minimize bias in decision-making. Ensure clinicians validate AI-driven diagnoses, preventing unjustified disparities. By actively addressing bias, AI can enhance equity in healthcare and ensure that early detection of NCDs benefits all patient groups equally. In the United States, HIPAA establishes standards for the secure handling of medical information. AI-driven healthcare systems must comply with HIPAA by; Restricting access to patient records (Gerke *et al.*, 2020) [20]. Allowing patients to access and manage their health data. Implementing encryption and multi-factor authentication. In the European Union, GDPR governs the collection, processing, and storage of personal data, including medical information. Key principles include; Patients must provide explicit consent before their data is used in AI models. Individuals can request the deletion of their health records from databases. AI developers and healthcare providers must demonstrate compliance through audits and documentation. Other regions have their own healthcare data protection laws, such as the Personal Data Protection Act (PDPA) in Singapore and the Data Protection Act (DPA) in the UK. AI developers must ensure compliance with local regulations wherever the system is deployed.



**Fig 3:** Ethical and Regulatory Considerations

One of the major ethical concerns in AI-driven healthcare is the "black box" nature of some models, where decision-making processes are not easily interpretable. To enhance trust, AI systems should; Provide clear reasoning for each diagnosis or risk prediction (Alam and Mueller, 2021) [7]. Ensure healthcare professionals and patients can understand AI-generated recommendations. Allow for Clinical Oversight: AI should assist rather than replace human medical expertise. Patients must be informed about how AI is being used in their diagnosis and treatment plans. Ethical AI implementation requires; Informing patients about AI involvement in their healthcare decisions (Lysaght *et al.*, 2019) [32]. Allowing patients to refuse AI-based assessments

if they prefer traditional methods. Adapting AI deployment strategies based on local ethical standards and patient preferences. Determining responsibility for AI-driven medical errors presents a legal and ethical challenge. Questions arise regarding; Who is responsible for misdiagnoses? The AI developers, healthcare providers, or regulatory bodies? How should errors be addressed? Establishing clear legal frameworks for AI accountability. AI models must be regularly updated and validated to minimize risks of incorrect predictions.

While AI can improve the speed and accuracy of NCD detection, it must not compromise the human aspect of medical care. Ethical deployment should ensure; Healthcare professionals must remain central to patient care. Systems should be designed to enhance patient-doctor communication rather than depersonalize care. Ethical considerations should prioritize patient health over technological advancements. Ethical and regulatory considerations are critical in the development and implementation of AI-driven early detection systems for NCDs (Barrett *et al.*, 2019) [13]. Protecting patient privacy through robust data security measures, mitigating bias for equitable healthcare outcomes, ensuring compliance with global regulations (HIPAA, GDPR), and addressing ethical challenges related to AI-based medical decisions are all essential components of responsible AI deployment. By prioritizing transparency, accountability, and patient-centric care, AI can revolutionize disease detection while maintaining ethical integrity in healthcare.

## 2.5 Case Studies and Pilot Programs

The integration of artificial intelligence (AI) into healthcare has revolutionized early disease detection, particularly for Non-Communicable Diseases (NCDs) such as cardiovascular diseases, cancer, diabetes, and chronic respiratory conditions. Several case studies and pilot programs worldwide have demonstrated the effectiveness of AI-driven early detection systems. This explores notable examples, key lessons from successful implementations, and the challenges faced along with their solutions.

Google's DeepMind, in collaboration with Moorfields Eye Hospital in the UK, developed an AI system for detecting diabetic retinopathy (DR), a major cause of blindness among diabetics. Using deep learning algorithms trained on retinal images, the AI achieved an accuracy comparable to ophthalmologists (Ting *et al.*, 2019) [57]. The system was implemented in screening programs in India and Thailand, where there is a shortage of trained specialists. Reduced screening time and improved early detection rates. Increased accessibility to eye disease diagnosis in underserved regions. IBM Watson for Oncology utilizes AI to assist doctors in diagnosing and recommending treatment plans for cancer patients. By analyzing vast amounts of medical literature and patient data, Watson provides evidence-based treatment suggestions. The system has been deployed in hospitals across India, China, and the US. Enhanced clinical decision-making with AI-assisted treatment recommendations. Improved efficiency in diagnosing rare and complex cancers.

Researchers at the University of Oxford developed an AI model that analyzes MRI scans to detect early signs of cardiovascular diseases. The AI system uses machine learning to predict the likelihood of heart failure by examining heart structure and function. More accurate risk

assessment compared to traditional diagnostic tools. Improved patient outcomes through early intervention. AI-based image analysis systems, such as those developed by Google Health and Tencent, have been used to detect lung cancer in CT scans (Zhang *et al.*, 2020) [63]. Studies have shown that AI can detect malignant nodules more accurately than radiologists, leading to earlier diagnosis and treatment. Increased sensitivity and specificity in lung cancer detection. Reduced false positives and unnecessary biopsies. Wearable health technologies from companies like Apple and Fitbit incorporate AI algorithms to detect irregular heart rhythms, monitor glucose levels, and predict hypertension risks. These devices provide real-time alerts to users and healthcare providers, enabling early intervention. Empowered patients with continuous health monitoring. Reduced hospital admissions through proactive disease management.

AI systems rely on large, diverse, and high-quality datasets for accurate predictions. The success of DeepMind's diabetic retinopathy model highlights the necessity of well-annotated medical images from diverse populations. Healthcare institutions must prioritize data collection, standardization, and curation. AI-based solutions are most effective when seamlessly integrated into clinical workflows. IBM Watson's deployment in hospitals demonstrated that AI should complement, not replace, human expertise. AI tools must align with medical workflows to enhance, rather than disrupt, healthcare delivery (Reddy *et al.*, 2019) [48]. AI models must undergo rigorous validation and periodic updates to maintain accuracy. The UK Biobank cardiovascular study emphasized the importance of continuous learning for AI systems to adapt to evolving healthcare data. Ongoing training and validation are essential for AI reliability and accuracy. Google's AI-driven eye screening project in Thailand faced initial challenges related to patient consent and data privacy. Successful implementation required adherence to strict regulatory frameworks, such as HIPAA and GDPR. Ethical AI deployment requires transparency, patient consent, and compliance with global healthcare regulations. In lung cancer detection programs, AI-assisted radiologists outperformed AI-only and human-only assessments. This highlights the need for AI to support, rather than replace, medical professionals. Optimal results are achieved when AI augments clinical expertise rather than replacing human judgment. AI-driven early detection systems have demonstrated immense potential in identifying NCDs at earlier stages, improving patient outcomes, and reducing healthcare costs. Case studies such as Google's diabetic retinopathy model, IBM Watson for Oncology, AI-based cardiovascular risk prediction, and wearable health monitoring technologies highlight the transformative impact of AI in disease detection. Key lessons from successful implementations emphasize the need for high-quality data, seamless healthcare integration, continuous validation, ethical compliance, and human-AI collaboration. Despite challenges related to privacy, bias, adoption, costs, and regulations, ongoing advancements in AI technology, regulatory frameworks, and clinician engagement will drive the future of AI-powered early disease detection (Harvey and Gowda, 2021) [21].

## 2.6 Future Directions and Innovations

Artificial intelligence (AI) has already demonstrated significant potential in transforming healthcare, particularly in the early detection of non-communicable diseases (NCDs) such as cancer, cardiovascular diseases, diabetes, and neurodegenerative disorders. As AI technology evolves, its integration with predictive analytics, personalized medicine, and preventive healthcare strategies will further enhance its impact (Johnson *et al.*, 2021) [30]. This explores future advancements in AI for healthcare, the role of AI in personalized medicine, preventive strategies, and key research and development needs.

The continuous evolution of AI, particularly in machine learning (ML) and deep learning (DL), is driving the development of more accurate and efficient predictive models for disease detection. Several promising advancements are shaping the future of AI in healthcare: Future AI models will incorporate advanced neural networks capable of detecting complex patterns in multimodal medical data, such as imaging, genomic sequences, and clinical records. These models will improve diagnostic accuracy and reduce false positives. One of the major challenges in AI-driven healthcare is the "black box" nature of deep learning algorithms. Explainable AI will enhance transparency by providing interpretable results, allowing clinicians to understand and trust AI-driven predictions (Amann *et al.*, 2020) [10]. This technique allows multiple institutions to collaborate on AI model training without sharing sensitive patient data. By leveraging distributed computing, federated learning will improve model generalizability while ensuring data privacy and security. The integration of AI with multi-omics data (genomics, proteomics, and metabolomics) will lead to better understanding of disease mechanisms, facilitating earlier and more precise disease detection. These advancements will contribute to more effective and scalable AI-driven early detection systems, ultimately reducing the burden of NCDs on healthcare systems.

Personalized medicine aims to tailor medical treatments to an individual's genetic makeup, lifestyle, and environmental factors. AI will play a crucial role in optimizing personalized treatment strategies by; AI models can analyze genetic predispositions, lifestyle habits, and environmental exposures to provide personalized risk assessments for NCDs, allowing for targeted prevention strategies. AI can analyze genetic biomarkers and patient history to recommend personalized treatment options, reducing trial-and-error approaches in disease management (Strianese *et al.*, 2020) [54]. AI will accelerate the development of precision drugs by identifying genetic factors influencing drug efficacy and side effects, leading to safer and more effective treatments. AI-powered wearable devices and remote monitoring systems will provide real-time insights into an individual's health, enabling continuous adjustments to treatment plans based on real-time data. By integrating AI with personalized medicine, healthcare providers can move toward a patient-centric approach that optimizes treatment effectiveness while minimizing adverse effects.

AI has the potential to shift healthcare from reactive treatment to proactive disease prevention. Some of the key innovations in AI-driven preventive healthcare include;

AI can identify high-risk individuals before symptoms appear, allowing for early interventions that prevent disease progression. AI-driven applications can provide personalized lifestyle recommendations based on real-time health data, encouraging healthier behaviors to reduce disease risk (Wänn, 2019) [62]. Chatbots and AI-powered virtual assistants can provide continuous health guidance, remind patients to take medications, and monitor symptoms for early warning signs. AI can assist governments and healthcare organizations in designing targeted public health initiatives by analyzing population health trends and predicting disease outbreaks. These AI-driven preventive strategies will not only improve individual health outcomes but also reduce the overall burden on healthcare systems by minimizing the need for costly treatments and hospitalizations. To fully realize the potential of AI in early disease detection and prevention, several areas require further research and development; AI models require large, high-quality datasets for training. Future research should focus on standardizing medical data formats and improving interoperability between healthcare systems to facilitate seamless data exchange (Spanakis *et al.*, 2021) [53]. AI models can exhibit biases due to imbalanced training data, leading to disparities in healthcare outcomes. Research should focus on developing fairness-aware algorithms that ensure equitable healthcare delivery across different demographic groups. With increasing AI integration in medical decision-making, robust regulatory frameworks must be established to ensure the safety, reliability, and ethical use of AI-driven diagnostics. Future studies should explore optimal ways to integrate AI with clinical workflows, ensuring that AI supports rather than replaces human expertise. AI-driven healthcare solutions should be designed for scalability, making them accessible to low-resource settings where the burden of NCDs is often highest (Iyawa *et al.*, 2020) [26]. Research should focus on developing low-cost AI tools for early disease detection in underserved communities. By addressing these research and development needs, AI-driven healthcare solutions can achieve greater accuracy, reliability, and inclusivity, ensuring that AI benefits are realized across diverse populations. The future of AI in healthcare is poised for transformative advancements, with AI-driven early detection systems playing a critical role in reducing the burden of NCDs (Nicholson *et al.*, 2020) [40]. Advancements in deep learning, explainable AI, and federated learning will enhance predictive analytics, while AI integration with personalized medicine will enable tailored treatment plans. AI-powered preventive healthcare strategies will shift the focus from disease management to proactive health maintenance, improving overall patient outcomes. However, to fully leverage AI's potential, ongoing research and development efforts must address challenges related to data standardization, bias mitigation, regulatory compliance, and accessibility. By focusing on these future directions and innovations, AI-driven healthcare can revolutionize early disease detection and prevention, ultimately contributing to a healthier global population (Das, 2019) [15].

### 3. Conclusion

The development and implementation of AI-driven early detection systems have the potential to revolutionize the management of non-communicable diseases (NCDs). Throughout this discussion, we have explored key aspects of

AI's role in NCD detection, from technological advancements to ethical considerations and future research directions. AI technologies, particularly machine learning and deep learning, are transforming healthcare by enabling accurate and timely disease detection, integrating diverse data sources, and enhancing predictive analytics.

One of the most significant findings is that AI-driven models can improve early diagnosis through advanced pattern recognition, leveraging data from electronic health records (EHRs), wearable devices, and genomic data. These technologies help identify high-risk individuals, allowing for early interventions that reduce disease progression and improve patient outcomes. Moreover, AI-powered diagnostic tools, such as imaging and biomarker analysis, are proving to be more efficient and accurate than traditional detection methods. However, challenges such as data privacy, bias in AI models, and regulatory compliance must be addressed to ensure equitable and ethical healthcare delivery.

AI is not just an analytical tool; it is a transformative force in healthcare. By integrating AI into NCD management, healthcare providers can shift from reactive treatment to proactive prevention. AI-driven personalized medicine and predictive analytics will enable tailored treatment plans, while virtual health assistants and remote monitoring will enhance patient engagement and adherence to medical recommendations.

To maximize the benefits of AI-driven early detection systems, healthcare stakeholders including policymakers, medical professionals, and technology developers must collaborate. Investments in AI research, regulatory frameworks, and infrastructure development are essential to ensure safe, effective, and accessible AI-powered healthcare solutions. By addressing these challenges and embracing AI-driven innovations, healthcare systems can improve disease prevention, reduce mortality rates, and enhance the overall quality of life for individuals at risk of NCDs.

### 4. References

1. Adelodun AM, Adekanmi AJ, Roberts A, Adeyinka AO. Effect of asymptomatic malaria parasitemia on the uterine and umbilical artery blood flow impedance in third-trimester singleton Southwestern Nigerian pregnant women. *Tropical Journal of Obstetrics and Gynaecology*. 2018; 35(3):333-341.
2. Adepoju PA, Austin-Gabriel B, Ige AB, Hussain NY, Amoo OO, Afolabi AI. Machine learning innovations for enhancing quantum-resistant cryptographic protocols in secure communication. *Open Access Research Journal of Multidisciplinary Studies*. 2022; 4(1):131-139.
3. Adewoyin MA. Developing frameworks for managing low-carbon energy transitions: Overcoming barriers to implementation in the oil and gas industry, 2021.
4. Agho G, Ezeh MO, Isong M, Iwe D, Oluseyi KA. Sustainable pore pressure prediction and its impact on geo-mechanical modelling for enhanced drilling operations. *World Journal of Advanced Research and Reviews*. 2021; 12(1):540-557.
5. Ajayi A, Akerele JI. A high-impact data-driven decisionmaking model for integrating cutting-edge cybersecurity strategies into public policy, governance, and organizational frameworks. *International Journal of Multidisciplinary Research and Growth Evaluation*.

- 2021; 2(1):623-637.
6. Akinade AO, Adepoju PA, Ige AB, Afolabi AI, Amoo OO. A conceptual model for network security automation: Leveraging AI-driven frameworks to enhance multi-vendor infrastructure resilience. *International Journal of Science and Technology Research Archive*. 2021; 1(1):39-59.
  7. Alam L, Mueller S. Examining the effect of explanation on satisfaction and trust in AI diagnostic systems. *BMC medical informatics and decision making*. 2021; 21(1):p.178.
  8. Ali L, Rahman A, Khan A, Zhou M, Javeed A, Khan JA. An automated diagnostic system for heart disease prediction based on  $\chi^2$  statistical model and optimally configured deep neural network. *IEEE Access*. 2019; 7:34938-34945.
  9. Alli OI, Dada SA. Innovative Models for Tobacco Dependency Treatment: A Review of Advances in Integrated Care Approaches in High-Income Healthcare Systems. *IRE Journals*. 2021; 5(6):273-282.
  10. Amann J, Blasimme A, Vayena E, Frey D, Madai VI, Precise4Q Consortium. Explainability for artificial intelligence in healthcare: A multidisciplinary perspective. *BMC Medical Informatics and Decision Making*. 2020; 20:1-9.
  11. Atta JA, Al Zoubi MAM, Temedie-Asogwa T, Amafah J. Comparing the Cost-Effectiveness of Pharmaceutical vs. Non-Pharmaceutical Interventions for Diabetes Management, 2021.
  12. Austin-Gabriel B, Hussain NY, Ige AB, Adepoju PA, Amoo OO, Afolabi AI. Advancing zero trust architecture with AI and data science for enterprise cybersecurity frameworks. *Open Access Research Journal of Engineering and Technology*. 2021; 1(1):47-55.
  13. Barrett M, Boyne J, Brandts J, Brunner-La Rocca HP, De Maesschalck L, De Wit K, *et al.* Artificial intelligence supported patient self-care in chronic heart failure: A paradigm shift from reactive to predictive, preventive and personalised care. *Epma Journal*. 2019; 10:445-464.
  14. Bidemi AI, Oyindamola FO, Odum I, Stanley OE, Atta JA, Olatomide AM, *et al.* Challenges Facing Menstruating Adolescents: A Reproductive Health Approach. *Journal of Adolescent Health*. 2021; 68(5):1-10.
  15. Das J. Revolutionizing Medical Imaging with Artificial Intelligence: Advancements, Challenges, and Future Directions in Diagnostic Precision. *International Journal of Enhanced Research in Management & Computer Applications*. 2019; 8:11-26.
  16. Dienagha IN, Onyeke FO, Digiemie WN, Adekunle M. Strategic reviews of greenfield gas projects in Africa: Lessons learned for expanding regional energy infrastructure and security, 2021.
  17. Dirlikov E, Jahun I, Odafe SF, Obinna O, Onyenuobi C, Ifunanya M, *et al.* Section navigation rapid scale-up of an antiretroviral therapy program before and during the COVID-19 pandemic-nine states, Nigeria, March 31, 2019-September 30, 2020, 2021.
  18. Elujide I, Fashoto SG, Fashoto B, Mbunge E, Folorunso SO, Olamijuwon JO. *Informatics in Medicine Unlocked*, 2021.
  19. Elujide I, Fashoto SG, Fashoto B, Mbunge E, Folorunso SO, Olamijuwon JO. Application of deep and machine learning techniques for multi-label classification performance on psychotic disorder diseases. *Informatics in Medicine Unlocked*. 2021; 23:p.100545.
  20. Gerke S, Minssen T, Cohen G. Ethical and legal challenges of artificial intelligence-driven healthcare. In *Artificial intelligence in healthcare*. Academic Press, 2020, 295-336.
  21. Harvey HB, Gowda V. Regulatory issues and challenges to artificial intelligence adoption. *Radiologic Clinics*. 2021; 59(6):1075-1083.
  22. Hassan YG, Collins A, Babatunde GO, Alabi AA, Mustapha SD. AI-driven intrusion detection and threat modeling to prevent unauthorized access in smart manufacturing networks. *Artificial Intelligence (AI)*, 2021, p.16.
  23. Hughes L, Sweeney D, Kasunic M. Planning and Design Considerations for On-Premises Computing Environments, 2021.
  24. Hussain NY, Austin-Gabriel B, Ige AB, Adepoju PA, Amoo OO, Afolabi AI. AI-driven predictive analytics for proactive security and optimization in critical infrastructure systems. *Open Access Research Journal of Science and Technology*. 2021; 2(2):6-15.
  25. Ike CC, Ige AB, Oladosu SA, Adepoju PA, Amoo OO, Afolabi AI. Redefining zero trust architecture in cloud networks: A conceptual shift towards granular, dynamic access control and policy enforcement. *Magna Scientia Advanced Research and Reviews*. 2021; 2(1):74-86.
  26. Iyawa GE, Hamunyela S, Peters A, Akinsola S, Shaanika I, Akinmoyeje B, Mutelo S. Digital transformation and global health in Africa. *Handbook of Global Health*, 2020, 1-32.
  27. Jahun I, Dirlikov E, Odafe S, Yakubu A, Boyd AT, Bachanas P, *et al.* Ensuring optimal community HIV testing services in Nigeria using an enhanced community case-finding package (ECCP), October 2019-March 2020: Acceleration to HIV epidemic control. *HIV/AIDS-Research and Palliative Care*, 2021, 839-850.
  28. Jahun I, Said I, El-Imam I, Ehoche A, Dalhatu I, Yakubu A, *et al.* Optimizing community linkage to care and antiretroviral therapy initiation: Lessons from the Nigeria HIV/AIDS Indicator and Impact Survey (NAIIS) and their adaptation in Nigeria ART Surge. *PLoS One*. 2021; 16(9):p.e0257476.
  29. Jeddi Z, Bohr A. Remote patient monitoring using artificial intelligence. In *Artificial intelligence in healthcare*. Academic Press, 2020, 203-234.
  30. Johnson KB, Wei WQ, Weeraratne D, Frisse ME, Misulis K, Rhee K, *et al.* Precision medicine, AI, and the future of personalized health care. *Clinical and Translational Science*. 2021; 14(1):86-93.
  31. Kuo YM, Nwankwo EI, Nussbaum RL, Rogers J, Maccicchini ML. Translational inhibition of  $\alpha$ -synuclein by Posiphen normalizes distal colon motility in transgenic Parkinson mice. *American Journal of Neurodegenerative Disease*. 2019; 8(1):p.1.
  32. Lysaght T, Lim HY, Xafis V, Ngiam KY. AI-assisted decision-making in healthcare: The application of an ethics framework for big data in health and research. *Asian Bioethics Review*. 2019; 11:299-314.

33. Mahmood U, Shrestha R, Bates DD, Mannelli L, Corrias G, Erdi YE, *et al.* Detecting spurious correlations with sanity tests for artificial intelligence guided radiology systems. *Frontiers in Digital Health.* 2021; 3:p.671015.
34. Makanjee CR. Diagnostic medical imaging services with myriads of ethical dilemmas in a contemporary healthcare context: Is artificial intelligence the solution? In *Medical Imaging Methods.* CRC Press, 2021, 1-44.
35. Matthew A, Opia FN, Matthew KA, Kumolu AF, Matthew TF. *Cancer Care Management in the COVID-19 Era: Challenges and adaptations in the global south.* *Cancer.* 2021; 2(6).
36. Matthew KA, Akinwale FM, Opia FN, Adenike A. *The Relationship between oral Contraceptive Use, Mammographic Breast Density, and Breast Cancer Risk,* 2021.
37. Mooney LA, Fay L, DeCastro B, Zanki TA, Mansi B. Transparency and credibility of industry-sponsored clinical trial publications: A survey of journal editors. *Current Medical Research and Opinion,* 2019.
38. Naseem M, Akhund R, Arshad H, Ibrahim MT. Exploring the potential of artificial intelligence and machine learning to combat COVID-19 and existing opportunities for LMIC: A scoping review. *Journal of Primary Care & Community Health.* 2020; 11:p.2150132720963634.
39. Nasuti C, Falcioni ML, Nwankwo IE, Cantalamessa F, Gabbianelli R. Effect of permethrin plus antioxidants on locomotor activity and striatum in adolescent rats. *Toxicology.* 2008; 251(1-3):45-50.
40. Nicholson A, Pavlin J, Buckley G, Amponsah E, National Academies of Sciences, Engineering, Medicine. *Nurturing Innovations Through Novel Ecosystems to Accelerate Research and Development.* In *Exploring the Frontiers of Innovation to Tackle Microbial Threats: Proceedings of a Workshop.* National Academies Press (US), May 2020.
41. Nwaozumudoh MO, Odio PE, Kokogho E, Olorunfemi TA, Adeniji IE, Sobowale A. Developing a conceptual framework for enhancing interbank currency operation accuracy in Nigeria's banking sector. *International Journal of Multidisciplinary Research and Growth Evaluation.* 2021; 2(1):481-494.
42. Odio PE, Kokogho E, Olorunfemi TA, Nwaozumudoh MO, Adeniji IE, Sobowale A. Innovative financial solutions: A conceptual framework for expanding SME portfolios in Nigeria's banking sector. *International Journal of Multidisciplinary Research and Growth Evaluation.* 2021; 2(1):495-507.
43. Oladosu SA, Ike CC, Adepoju PA, Afolabi AI, Ige AB, Amoo OO. Advancing cloud networking security models: Conceptualizing a unified framework for hybrid cloud and on-premises integrations. *Magna Scientia Advanced Research and Reviews,* 2021.
44. Olamijuwon OJ. *Real-time Vision-based Driver Alertness Monitoring using Deep Neural Network Architectures* (Master's thesis, University of the Witwatersrand, Johannesburg (South Africa)), 2020.
45. Oluokun OA. *Design of a Power System with Significant Mass and Volume Reductions, Increased Efficiency, and Capability for Space Station Operations Using Optimization Approaches* (Doctoral dissertation, McNeese State University), 2021.
46. Oyedokun OO. *Green human resource management practices and its effect on the sustainable competitive edge in the Nigerian manufacturing industry (Dangote)* (Doctoral dissertation, Dublin Business School), 2019.
47. Paulus JK, Kent DM. Predictably unequal: understanding and addressing concerns that algorithmic clinical prediction may increase health disparities. *NPJ Digital Medicine.* 2020; 3(1):p.99.
48. Reddy S, Fox J, Purohit MP. Artificial intelligence-enabled healthcare delivery. *Journal of the Royal Society of Medicine.* 2019; 112(1):22-28.
49. Schwalbe N, Wahl B. Artificial intelligence and the future of global health. *The Lancet.* 2020; 395(10236):1579-1586.
50. Senbekov M, Saliev T, Bukeyeva Z, Almabayeva A, Zhanaliyeva M, Aitenova N, *et al.* The recent progress and applications of digital technologies in healthcare: A review. *International Journal of Telemedicine and Applications.* 2020; 1:p.8830200.
51. Shiroya V, Neuhann F, Müller O, Deckert A. Challenges in policy reforms for non-communicable diseases: The case of diabetes in Kenya. *Global Health Action.* 2019; 12(1):p.1611243.
52. Soon S, Svavarsdottir H, Downey C, Jayne DG. Wearable devices for remote vital signs monitoring in the outpatient setting: An overview of the field. *BMJ Innovations.* 2020; 6(2).
53. Spanakis EG, Sfakianakis S, Bonomi S, Ciccotelli C, Magalini S, Sakkalis V. Emerging and established trends to support secure health information exchange. *Frontiers in Digital Health.* 2021; 3:p.636082.
54. Strianese O, Rizzo F, Ciccarelli M, Galasso G, D'Agostino Y, Salvati A, *et al.* Precision and personalized medicine: How genomic approach improves the management of cardiovascular and neurodegenerative disease. *Genes.* 2020; 11(7):p.747.
55. Tayebati Khosrow S, Ejike Nwankwo I, Amenta F. Intranasal drug delivery to the central nervous system: Present status and future outlook. *Current Pharmaceutical Design.* 2013; 19(3):510-526.
56. Tayebati Khosrow S, Tomassoni D, Ejike Nwankwo I, Di Stefano A, Sozio P, Serafina Cerasa L, *et al.* Modulation of monoaminergic transporters by choline-containing phospholipids in rat brain. *CNS & Neurological Disorders-Drug Targets (Formerly Current Drug Targets-CNS & Neurological Disorders).* 2013; 12(1):94-103.
57. Ting DSW, Pasquale LR, Peng L, Campbell JP, Lee AY, Raman R, *et al.* Artificial intelligence and deep learning in ophthalmology. *British Journal of Ophthalmology.* 2019; 103(2):167-175.
58. Tomassoni D, Amenta F, Amantini C, Farfariello V, Di Cesare Mannelli L, Nwankwo IE, *et al.* Brain activity of thioctic acid enantiomers: *In vitro* and *in vivo* studies in an animal model of cerebrovascular injury. *International Journal of Molecular Sciences.* 2013; 14(3):4580-4595.
59. Tomassoni D, Amenta F, Di Cesare Mannelli L, Ghelardini C, Nwankwo IE, Pacini A, *et al.* Neuroprotective activity of thioctic acid in central nervous system lesions consequent to peripheral nerve injury. *BioMed Research International.* 2013; 2013(1):p.985093.
60. Tomassoni D, Catalani A, Cinque C, Antonietta Di Tullio M, Khosrow Tayebati S, Cadoni A, *et al.* Effects

- of cholinergic enhancing drugs on cholinergic transporters in the brain and peripheral blood lymphocytes of spontaneously hypertensive rats. *Current Alzheimer Research*. 2012; 9(1):120-127.
61. Tomassoni D, Nwankwo IE, Gabrielli MG, Bhatt S, Muhammad AB, Lokhandwala MF, *et al.* Astrogliosis in the brain of obese Zucker rat: A model of metabolic syndrome. *Neuroscience Letters*. 2013; 543:136-141.
62. Wänn D. Personalized predictive health care: How predictive AI platforms will transform the health care industry. In *Digital transformation and public services*. Routledge, 2019, 97-116.
63. Zhang K, Liu X, Shen J, Li Z, Sang Y, Wu X, *et al.* Clinically applicable AI system for accurate diagnosis, quantitative measurements, and prognosis of COVID-19 pneumonia using computed tomography. *Cell*. 2020; 181(6):1423-1433.